Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Doug Elmendorf to head CBO

Executive Summary

Having started his non-academic career as a Congressional Budget Office analyst whose purview included health care reform, Douglas Elmendorf is returning to the agency to succeed Peter Orszag as director. During his first stint at the budget agency in 1993-95, Elmendorf's output included analysis of the economic effects of the Clinton Administration health care proposals and options for controlling private health insurance premiums. Since leaving CBO in 1995, the Harvard-educated economist has served in senior positions at Treasury, the Federal Reserve Board and the Council of Economic Advisers. He currently is director of the Hamilton Project at the Brookings Institution. Orszag, who will lead the Office of Management and Budget in the Obama Administration, was the first director of that project, which generates ideas for promoting broad-based economic growth. CBO has helped kicked off the health reform debate with a late December report scoring the budget impact of various reform options. Speaker of the House Nancy Pelosi announced the selection of Elmendorf Dec. 30

You may also be interested in...

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts